Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cronos Group Inc (CRON) vs Teradyne, Inc. (TER) Price & Performance

Cronos Group IncTrade
Teradyne, Inc.Trade

Price performance (Past 24H)

Key statistics

Cronos Group Inc vs Teradyne, Inc. — how do they compare? Cronos Group Inc trades at $3.08 (market cap $1.11B), while Teradyne, Inc. trades at $382.24 (market cap $57.08B). The key difference: Teradyne, Inc. is far larger — about 51.4× Cronos Group Inc's market cap, and Teradyne, Inc. pays a 0.14% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.

CRONTER
Market Cap
$1.11B$57.08B
Sector
HealthTechnology
52-Week High
$3.27$483.84
52-Week Low
$2.30$109.30
Enterprise Value
$310.67M$56.83B
Dividend Yield
0.14%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cronos Group Inc

CRON trades at $3.10 with a 0.98% daily gain, showing bullish technical momentum. The company delivered strong Q2 2026 results with 58% YoY revenue growth and earnings beat, while maintaining #1 market share in Canadian vapes and edibles. Despite negative net income in 2025, revenue growth accelerated to $147M with improving margins. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near $3 resistance.

Outlook remains positive with international expansion and European cannabis legalization driving growth, though competitive pressures and execution risks persist. Analyst consensus is mixed with 60% hold ratings, reflecting cautious optimism about CRON's turnaround trajectory from previous losses to projected 39% profit margin by 2026.

Teradyne, Inc.

Teradyne (TER) trades at $379.31, down 1.45% today but maintains strong technical momentum with a bullish moving average signal. The company demonstrates robust fundamentals with record Q2 2026 earnings of $2.47 EPS beating estimates by 18%, driven by AI-led semiconductor test demand. Revenue grew to $3.19 billion in 2025 with impressive 25.77% net income margin and 36.66% ROE. Analyst consensus remains strongly bullish with 64.5% buy ratings and $481.63 price target representing 27% upside potential.

Teradyne presents compelling growth prospects fueled by AI-driven semiconductor testing demand and expanding robotics business. The stock trades at premium valuations (P/E 52.1, P/S 13.43) reflecting high growth expectations. Key risks include cyclical semiconductor industry exposure and execution challenges in scaling operations. Current technical positioning near pivot point ($384) suggests potential for breakout above resistance at $396 if earnings momentum continues through Q3 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cronos Group Inc

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.

Read more on CRON

About Teradyne, Inc.

Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.

Read more on TER